Tozorakimab-placebo, Tozorakimab, SALBUTAMOL
D9180C00003
Phase 3 small_molecule active
Quick answer
Tozorakimab-placebo, Tozorakimab, SALBUTAMOL for Chronic Obstructive Pulmonary Disease (COPD) is a Phase 3 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca AB
- Indication
- Chronic Obstructive Pulmonary Disease (COPD)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active